文献速递肝病

2020年非酒精性脂肪性肝病治疗格局

Therapeutic Landscape for NAFLD in 2020.
PubMed 文献 · Gastroenterology · 2020-02-13

综述指出,NASH患者首选生活方式干预,但依从性常不理想;为阻止肝硬化及肝癌等并发症,目前正开展针对能量摄入、能量处置、脂毒性肝损伤及炎症纤维化的药物临床试验,重点为2期和3期药物,未来可能走向个体化治疗。

要点

  • 生活方式干预是NASH首选推荐,但患者常难以长期坚持。
  • 药物研发靶点包括能量摄入、能量处置、脂毒性肝损伤及炎症纤维化。
  • NASH表型由多种机制导致,未来治疗可能趋向个体化。

核心结论

  • 生活方式干预仍是NASH主要推荐,但常难以成功。
  • 为阻止NASH流行及其并发症,药物干预正在临床试验中评估。
  • NASH由多种机制导致,未来最佳治疗可能演变为个体化方案。

研究设计与样本

  • 综述,重点讨论2期和3期临床试验中的NASH治疗药物。

主要发现

  • 生活方式干预聚焦健康饮食和规律运动,是NASH患者的主要推荐。
  • 由于社会、心理、身体、遗传和表观遗传等多重原因,患者采纳并维持生活方式改变具有挑战性且通常不成功。
  • 药物靶点包括能量摄入、能量处置、脂毒性肝损伤以及导致肝硬化的炎症和纤维化。

临床怎么用

  • 临床应继续将健康饮食和规律运动作为NASH主要推荐。
  • 关注2期和3期在研药物,为未来个体化治疗做准备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lifestyle modifications focused on healthy eating and regular exercise are the primary recommendations for patients with nonalcoholic steatohepatitis (NASH). However, for multiple societal, psychological, physical, genetic, and epigenetic reasons, the ability of people to adopt and sustain such changes is challenging and typically not successful. To end the epidemic of NASH and prevent its complications, including cirrhosis and hepatocellular carcinoma, pharmacological interventions are now being evaluated in clinical trials. Treatments include drugs targeting energy intake, energy disposal, lipotoxic liver injury, and the resulting inflammation and fibrogenesis that lead to cirrhosis. It is likely that patients develop the phenotype of NASH by multiple mechanisms, and thus the optimal treatments of NASH will likely evolve to personalized therapy once we understand the mechanistic underpinnings of NASH in each patient. Reviewed here is the treatment landscape in this rapidly evolving field with an emphasis on drugs in Phase 2 and Phase 3 trials.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology. 2020. PMID: 32061596. doi:10.1053/j.gastro.2020.01.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。